ORIC Pharmaceuticals, Inc.

Equities

ORIC

US68622P1093

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 12:14:27 2024-07-17 EDT			5-day change	1st Jan Change
10.24 ^USD	-6.78%		+10.72%	+12.28%

07-16	ORIC Pharmaceuticals, Inc. Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer	CI
07-01	ORIC Pharmaceuticals, Inc.(NasdaqGS:ORIC) added to Russell Microcap Growth Index	CI

ORIC Pharmaceuticals, Inc. Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

July 16, 2024 at 04:59 pm

ORIC Pharmaceuticals, Inc. announced it initiated dosing of ORIC-944, a potent and selective allosteric inhibitor of PRC2, in combination with darolutamide as well as in combination with apalutamide, in the first half of 2024 as part of the ongoing Phase 1b trial in patients with metastatic prostate cancer. Each combination cohort includes a dose escalation and expansion portion, evaluating the combination of ORIC-944 and NUBEQA® (darolutamide) or ORIC-944 and ERLEADA® (apalutamide).

Latest news about ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc. Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer	07-16	CI
ORIC Pharmaceuticals, Inc.(NasdaqGS:ORIC) added to Russell Microcap Growth Index	06-30	CI
ORIC Pharmaceuticals, Inc.(NasdaqGS:ORIC) added to Russell 3000 Growth Index	06-30	CI
ORIC Pharmaceuticals, Inc.(NasdaqGS:ORIC) added to Russell 3000E Growth Index	06-30	CI
ORIC Pharmaceuticals, Inc.(NasdaqGS:ORIC) added to Russell 2000 Growth Index	06-30	CI
ORIC Pharmaceuticals, Inc.(NasdaqGS:ORIC) added to Russell 2500 Growth Index	06-30	CI
ORIC Pharmaceuticals, Inc.(NasdaqGS:ORIC) added to Russell Small Cap Comp Growth Index	06-30	CI
Transcript : ORIC Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM	06-10
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
ORIC Pharmaceuticals Doses First Patients in Expansion Groups in Phase 1b Trial of ORIC-114 to Treat Lung Cancer	04-15	MT
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC	04-15	CI
ORIC Pharmaceuticals, Inc Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research Annual Meeting	04-08	CI
JPMorgan Trims ORIC Pharmaceuticals' Price Target to $18 From $19, Maintains Overweight Rating	03-27	MT
HC Wainwright Adjusts ORIC Pharmaceuticals' Price Target to $21 From $15, Keeps Buy Rating	03-21	MT
ORIC Pharmaceuticals, Inc.(NasdaqGS:ORIC) added to S&P Biotechnology Select Industry Index	03-17	CI
Baird Cuts Price Target on ORIC Pharmaceuticals to $25 From $27, Maintains Outperform Rating	03-12	MT
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-11	CI
ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-11	CI
Oric Pharmaceuticals Insider Sold Shares Worth $648,380, According to a Recent SEC Filing	03-08	MT
Wedbush Adjusts Oric Pharmaceuticals' Price Target to $20 From $12, Maintains Outperform Rating	03-01	MT
Cantor Fitzgerald Initiates ORIC Pharmaceuticals at Overweight Rating	02-26	MT
Transcript : ORIC Pharmaceuticals, Inc. Presents at Citi 2024 Virtual Oncology Leadership Summit, Feb-21-2024 12:00 PM	02-21
Oric Pharmaceuticals Insider Sold Shares Worth $489,346, According to a Recent SEC Filing	02-09	MT
ORIC Pharmaceuticals, Inc. announced that it has received $125 million in funding from Viking Global Investors LP, Commodore Capital LP, Frazier Management, L.L.C., Frazier Life Sciences Management, LP, VR Adviser, LLC, Nextech Invest Ltd.	01-29	CI
ORIC Pharmaceuticals Launching $125 Million Private Placement	01-22	MT

Chart ORIC Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.99 USD

Average target price

19 USD

Spread / Average Target

+72.88%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ORIC PHARMACEUTICALS, INC.	+12.28%	741M
VERTEX PHARMACEUTICALS INCORPORATED	+18.05%	126B
REGENERON PHARMACEUTICALS, INC.	+23.04%	118B
ARGENX SE	+23.26%	27.87B
BIONTECH SE	-18.57%	20.95B
GENMAB A/S	-15.13%	16.92B
BEIGENE, LTD.	-15.57%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+9.33%	14.84B
WUXI APPTEC CO., LTD.	-46.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+52.09%	14.08B

Bio Therapeutic Drugs